Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Return on Assets (2016 - 2026)

Cartesian Therapeutics (RNAC) has disclosed Return on Assets for 11 consecutive years, with 0.49% as the latest value for Q1 2026.

  • For Q1 2026, Return on Assets fell 38.0% year-over-year to 0.49%; the TTM value through Mar 2026 reached 0.49%, down 38.0%, while the annual FY2025 figure was 0.36%, 15.0% down from the prior year.
  • Return on Assets hit 0.49% in Q1 2026 for Cartesian Therapeutics, down from 0.41% in the prior quarter.
  • Across five years, Return on Assets topped out at 0.15% in Q3 2022 and bottomed at 1.18% in Q4 2023.
  • Average Return on Assets over 5 years is 0.28%, with a median of 0.22% recorded in 2025.
  • Year-over-year, Return on Assets tumbled -130bps in 2023 and then surged 109bps in 2024.
  • Cartesian Therapeutics' Return on Assets stood at 0.12% in 2022, then tumbled by -1043bps to 1.18% in 2023, then skyrocketed by 93bps to 0.08% in 2024, then crashed by -399bps to 0.41% in 2025, then fell by -19bps to 0.49% in 2026.
  • According to Business Quant data, Return on Assets over the past three periods came in at 0.49%, 0.41%, and 0.22% for Q1 2026, Q4 2025, and Q3 2025 respectively.